Pfizer PFE unveils its next round of earnings this Tuesday, Jan. 29. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement
Earnings and Revenue
Pfizer EPS is expected to be around 64 cents, according to sell-side analysts. Sales will likely be near $13.95 billion.
In the same quarter last year, Pfizer posted a profit of 62 cents on sales of $13.70 billion. Sales would be up 1.8 percent from the year-ago period. Here's how the Pfizer's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
EPS Estimate | 0.75 | 0.74 | 0.74 | 0.56 |
EPS Actual | 0.78 | 0.81 | 0.77 | 0.62 |
Stock Performance
Over the last 52-week period, shares are up 10.05 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with Pfizer. The strength of this rating has maintained conviction over the past three months.
Conference Call
Pfizer is scheduled to hold a conference call at 10:00 a.m. ET and it can be accessed here: https://www.webcaster4.com/Webcast/Page/748/28670
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.